Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

The Impact of Type 2 Diabetes in Parkinson's Disease
Dilan Athauda, James R. Evans, Anna I. Wernick, et al.
Movement Disorders (2022) Vol. 37, Iss. 8, pp. 1612-1623
Open Access | Times Cited: 72

Showing 1-25 of 72 citing articles:

Microbiota–gut–brain axis and its therapeutic applications in neurodegenerative diseases
Jian Sheng Loh, Wen Qi Mak, Li Tan, et al.
Signal Transduction and Targeted Therapy (2024) Vol. 9, Iss. 1
Open Access | Times Cited: 237
Glucagon-like peptide-1 class drugs show clear protective effects in Parkinson's and Alzheimer's disease clinical trials: A revolution in the making?
Christian Hölscher
Neuropharmacology (2024) Vol. 253, pp. 109952-109952
Open Access | Times Cited: 24
Epidemiology of Parkinson’s Disease: An Update
Juan R. Deliz, Caroline M. Tanner, Paulina Gonzàlez‐Latapi
Current Neurology and Neuroscience Reports (2024) Vol. 24, Iss. 6, pp. 163-179
Closed Access | Times Cited: 17
Cholecystokinin (CCK): a neuromodulator with therapeutic potential in Alzheimer’s and Parkinson’s disease
Niklas Reich, Christian Hölscher
Frontiers in Neuroendocrinology (2024) Vol. 73, pp. 101122-101122
Open Access | Times Cited: 16
Associations Between Diabetes Mellitus and Neurodegenerative Diseases
Leszek Szablewski
International Journal of Molecular Sciences (2025) Vol. 26, Iss. 2, pp. 542-542
Open Access | Times Cited: 3
Disease continuum centered on Parkinson's disease
Ming Zheng
European Neuropsychopharmacology (2025) Vol. 93, pp. 19-21
Closed Access | Times Cited: 3
Plasma fibronectin is a prognostic biomarker of disability in Parkinson’s disease: a prospective, multicenter cohort study
Shuzhen Zhu, Hualin Li, Zifeng Huang, et al.
npj Parkinson s Disease (2025) Vol. 11, Iss. 1
Open Access | Times Cited: 2
Actions of Metformin in the Brain: A New Perspective of Metformin Treatments in Related Neurological Disorders
Nuojin Li, Tian Zhou, Erkang Fei
International Journal of Molecular Sciences (2022) Vol. 23, Iss. 15, pp. 8281-8281
Open Access | Times Cited: 41
Physical activity and lifestyle modifications in the treatment of neurodegenerative diseases
José A. Santiago, Judith A. Potashkin
Frontiers in Aging Neuroscience (2023) Vol. 15
Open Access | Times Cited: 32
Insulin resistance compromises midbrain organoid neuronal activity and metabolic efficiency predisposing to Parkinson’s disease pathology
Alise Žagare, Janis Kurlovics, Catarina Serra-Almeida, et al.
Journal of Tissue Engineering (2025) Vol. 16
Open Access | Times Cited: 1
Type 2 Diabetes and Parkinson's Disease: A Focused Review of Current Concepts
Patrick W. Cullinane, Eduardo De Pablo‐Fernández, Annekatrin König, et al.
Movement Disorders (2022) Vol. 38, Iss. 2, pp. 162-177
Closed Access | Times Cited: 33
How should we be using biomarkers in trials of disease modification in Parkinson’s disease?
Nirosen Vijiaratnam, Thomas Foltynie
Brain (2023) Vol. 146, Iss. 12, pp. 4845-4869
Open Access | Times Cited: 21
Diabetes: a tipping point in neurodegenerative diseases
José A. Santiago, M. Ganesh Karthikeyan, Madison Lackey, et al.
Trends in Molecular Medicine (2023) Vol. 29, Iss. 12, pp. 1029-1044
Open Access | Times Cited: 20
Type 2 Diabetes Mellitus and Neurodegenerative Disorders: The Mitochondrial Connection
Isabella R Baduini, Jose E Castro Vildosola, Sheida Kavehmoghaddam, et al.
Pharmacological Research (2024), pp. 107439-107439
Open Access | Times Cited: 7
Toxic interactions between dopamine, α-synuclein, monoamine oxidase, and genes in mitochondria of Parkinson’s disease
Makoto Naoi, Wakako Maruyama, Masayo Shamoto‐Nagai, et al.
Journal of Neural Transmission (2024) Vol. 131, Iss. 6, pp. 639-661
Closed Access | Times Cited: 5
The Contribution of Type 2 Diabetes to Parkinson’s Disease Aetiology
Samo Ribaric̀
International Journal of Molecular Sciences (2024) Vol. 25, Iss. 8, pp. 4358-4358
Open Access | Times Cited: 5
Predictors of cognitive impairment in newly diagnosed Parkinson’s disease with normal cognition at baseline: A 5-year cohort study
Jing Chen, Danhua Zhao, Qi Wang, et al.
Frontiers in Aging Neuroscience (2023) Vol. 15
Open Access | Times Cited: 13
Mortality and causes of death in patients with Parkinson's disease: a nationwide population-based cohort study
Dong-Woo Ryu, Kyungdo Han, A-Hyun Cho
Frontiers in Neurology (2023) Vol. 14
Open Access | Times Cited: 13
Association between diabetes mellitus, prediabetes and risk, disease progression of Parkinson's disease: A systematic review and meta-analysis
Qifan Zhong, Shenglong Wang
Frontiers in Aging Neuroscience (2023) Vol. 15
Open Access | Times Cited: 12
Update: Protective and risk factors for Parkinson disease
Nikolas Grotewold, Roger L. Albin
Parkinsonism & Related Disorders (2024) Vol. 125, pp. 107026-107026
Closed Access | Times Cited: 4
Advantages and Challenges of Platform Trials for Disease Modifying Therapies in Parkinson's Disease
Margherita Fabbri, Olivier Rascol, Thomas Foltynie, et al.
Movement Disorders (2024) Vol. 39, Iss. 9, pp. 1468-1477
Closed Access | Times Cited: 4
An update on drug repurposing in Parkinson’s disease: Preclinical and clinical considerations
Michela Salvadè, Mónica Di Luca, Fabrizio Gardoni
Biomedicine & Pharmacotherapy (2025) Vol. 183, pp. 117862-117862
Closed Access
Parkinson's disease and glucose metabolism impairment
Liangjing Chen, Chunyu Wang, Lixia Qin, et al.
Translational Neurodegeneration (2025) Vol. 14, Iss. 1
Open Access
Multi‐Targeting Macrocyclic Peptides as Nanomolar Inhibitors of Self‐ and Cross‐Seeded Amyloid Self‐Assembly of α‐Synuclein
Simon Hornung, Dominik P. Vogl, Denise Naltsas, et al.
Angewandte Chemie (2025)
Closed Access
Multi‐Targeting Macrocyclic Peptides as Nanomolar Inhibitors of Self‐ and Cross‐Seeded Amyloid Self‐Assembly of α‐Synuclein
Simon Hornung, Dominik P. Vogl, Denise Naltsas, et al.
Angewandte Chemie International Edition (2025)
Open Access
Page 1 - Next Page

Scroll to top